ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

Exploring Cabozantinib With Nivolumab and Ipilimumab in Urothelial Carcinoma

Andrea B. Apolo, MD
Published Online:2:52 PM, Mon September 18, 2017

Andrea B. Apolo, MD, principal investigator and the head of the Bladder Cancer Section in the Genitourinary Malignancies Branch at the National Cancer Institute’s Center for Cancer Research, discusses a phase I study of cabozantinib (Cabometyx) plus nivolumab (Opdivo) and cabozantinib plus nivolumab with ipilimumab (Yervoy) in patients with refractory metastatic urothelial carcinoma and other genitourinary tumors.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.